News ViiV wins US approval for HIV treatment in newborn babies The US FDA has green lit ViiV Healthcare’s Tivicay PD (dolutegravir) for the treatment of HIV-1 in children weighing at least 2 kg.
News OpenAI Foundation pledges $100m to boost hepatitis C cure ra... The OpenAI Foundation has committed $100m to help fund a new public health initiative initially focused on hepatitis C.
News HIV resurgence looming as international aid declines More than 3m people worldwide could be infected with HIV by the end of the decade following a steep fall in international aid funding, says UNAIDS.
News Gilead, MSD share data on once-weekly oral HIV treatment Gilead/MSD's once-weekly oral medicine for HIV has been shown to achieve high rates of viral suppression in phase 3, setting up regulatory filings.
News FDA starts kicks off review of Gilead's weekly HIV pill The FDA is due to deliver a verdict in February on Gilead's once-weekly pill for HIV PrEP, which could expand the options available to patients.
News ViiV ownership shifts as Pfizer sells its stake Pfizer will relinquish its stake in HIV firm ViiV in a deal valued at $2.1bn that ramps up Shionogi's interest and simplifies its share structure.
News ESC26: Isomab safety evidence on blood vessel growth for CAD Isomab has presented landmark safety data at ESC, clearing the path for next-generation therapies to promote blood vessel growth in CAD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.